La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?

• Ce qui fait monter. The NDA was filed in December 2025, placing the expected PDUFA decision date in the fourth quarter of 2026 [1].
• Ce qui fait monter. Head-to-head Phase 3 data released in September 2026 showed CagriSema achieved greater weight loss than Eli Lilly's tirzepatide in patients with type 2 diabetes [1, 5].
• Ce qui fait monter. Recent industry reports describe the FDA decision as 'near' as of early October 2026 [10].
• Ce qui fait monter. CagriSema is a combination of semaglutide (already FDA-approved) and cagrilintide, which may streamline the review process compared to a completely novel molecular entity.
• Ce qui fait descendre. The pivotal REDEFINE-1 trial missed Novo Nordisk's internal target of 25% weight loss, which the CEO characterized as part of 'mixed data' and 'setbacks' [1, 2].
• Ce qui fait descendre. The proximity of the expected decision to the December 31 deadline leaves no margin for a standard 3-month PDUFA extension, which is often triggered by the submission of major late-cycle data [1, 2].
• Ce qui fait descendre. A Complete Response Letter (CRL) or any administrative delay would result in a 'No' resolution for this specific timeframe.
• Ce qui fait descendre. There are three serious safety signals for cagrilintide recorded in the FAERS database, which may prompt additional regulatory scrutiny [FAERS Context].
• Ce qui ferait le plus bouger ce chiffre. Whether the 'mixed' results from the REDEFINE-1 trial or the late-stage data releases in August/September 2026 led to a major amendment of the NDA, which would automatically push the PDUFA date into early 2027.

• Ce qui fait monter. Positive efficacy data showing greater weight loss than Lilly rival (Reuters) [tier 2]
• Ce qui fait monter. Reports of superior weight loss in late‑stage diabetes trial (Pharmaceutical Executive) [tier 3]
• Ce qui fait descendre. Novo reports “couple of setbacks” in R&D and mixed data (Fierce Biotech) [tier 2]
• Ce qui fait descendre. Submaximal dose results suggest less than expected efficacy (Pharmaceutical Technology) [tier 3]
• Ce qui ferait le plus bouger ce chiffre. The official PDUFA date or any FDA communication confirming the review timeline would most shift the estimate.

• Ce qui fait monter. Positive trial data and strong Novo track record, as reported by Reuters [tier 2] and Pharmaceutical Executive [tier 3]
• Ce qui fait monter. NDA filed and review scheduled for 2026, indicating FDA intent to evaluate the product [tier 1]
• Ce qui fait descendre. Mixed data and missed weight‑loss target in REDEFINE‑1, reported by Pharmaceutical Technology [tier 3]
• Ce qui fait descendre. Safety signals in FAERS and industry concerns about potential regulatory delays, highlighted by Fierce Biotech and Investir Les Echos [tier 2]
• Ce qui ferait le plus bouger ce chiffre. Whether the FDA will issue a complete response letter or postpone the PDUFA date, which would delay or prevent approval by 31 Dec 2026.

• Ce qui fait monter. Industry trackers place the decision in Q4 2026, suggesting a higher likelihood of approval by the deadline. [tier 4]
• Ce qui fait monter. The NDA was filed on 18 Dec 2025 with a review scheduled in 2026, indicating the drug is in the first review cycle. [tier 4]
• Ce qui fait descendre. No official PDUFA date has been released, and the FDA has not yet issued a decision. [tier 4]
• Ce qui fait descendre. The lack of tier 1 or tier 2 confirmation means the information is weak and could be inaccurate. [tier 4]
• Ce qui ferait le plus bouger ce chiffre. The official PDUFA date and the actual FDA decision by 31 Dec 2026.

• Ce qui fait monter. The NDA was submitted on 18 December 2025 and accepted for review, keeping an official decision window within Q4 2026 [tier 1]
• Ce qui fait monter. CagriSema builds on semaglutide, an already FDA-approved moiety with an established safety profile [tier 1]
• Ce qui fait descendre. REDEFINE-1 missed its internal target of 25% weight loss, which could complicate label discussions or clinical evaluation [tier 1]
• Ce qui fait descendre. Any PDUFA extension or Complete Response Letter (CRL) before 31 December 2026 automatically results in a NO outcome [tier 1]
• Ce qui ferait le plus bouger ce chiffre. Whether the FDA issues a decision within the standard 10-month review window without requiring additional data or extending the PDUFA date into 2027.

Raisons non conservées pour cette révision (l'historique détaillé n'est gardé que depuis peu).

Raisons non conservées pour cette révision (l'historique détaillé n'est gardé que depuis peu).